IRIS
SILVESTRIS, Nicola
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 4.444
AS - Asia 3.099
NA - Nord America 2.821
SA - Sud America 1.197
AF - Africa 145
OC - Oceania 4
Totale 11.710
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.694
RU - Federazione Russa 2.468
SG - Singapore 1.319
BR - Brasile 980
IE - Irlanda 615
CN - Cina 522
HK - Hong Kong 517
IT - Italia 384
SE - Svezia 362
VN - Vietnam 242
DE - Germania 150
FR - Francia 107
IN - India 101
AR - Argentina 89
GB - Regno Unito 69
MX - Messico 69
FI - Finlandia 68
ID - Indonesia 65
AT - Austria 64
BD - Bangladesh 61
IQ - Iraq 52
NL - Olanda 39
EC - Ecuador 35
ZA - Sudafrica 32
TR - Turchia 29
MA - Marocco 28
CA - Canada 27
UZ - Uzbekistan 26
JP - Giappone 22
PK - Pakistan 22
PL - Polonia 21
CO - Colombia 19
VE - Venezuela 19
ES - Italia 18
UA - Ucraina 16
TN - Tunisia 15
EG - Egitto 14
PY - Paraguay 14
SA - Arabia Saudita 14
CL - Cile 13
DZ - Algeria 13
KE - Kenya 12
NP - Nepal 11
PE - Perù 11
UY - Uruguay 11
CZ - Repubblica Ceca 10
MY - Malesia 10
PH - Filippine 9
AE - Emirati Arabi Uniti 8
EE - Estonia 8
IL - Israele 8
TH - Thailandia 7
BO - Bolivia 6
ET - Etiopia 6
JO - Giordania 6
SN - Senegal 6
AL - Albania 5
AZ - Azerbaigian 5
CI - Costa d'Avorio 5
JM - Giamaica 5
PS - Palestinian Territory 5
SC - Seychelles 5
AO - Angola 4
BE - Belgio 4
CR - Costa Rica 4
HN - Honduras 4
IR - Iran 4
LK - Sri Lanka 4
LT - Lituania 4
OM - Oman 4
PA - Panama 4
SY - Repubblica araba siriana 4
AU - Australia 3
BA - Bosnia-Erzegovina 3
BG - Bulgaria 3
BY - Bielorussia 3
BZ - Belize 3
DO - Repubblica Dominicana 3
GR - Grecia 3
KG - Kirghizistan 3
LB - Libano 3
LV - Lettonia 3
MK - Macedonia 3
AM - Armenia 2
BH - Bahrain 2
GE - Georgia 2
HU - Ungheria 2
IS - Islanda 2
KZ - Kazakistan 2
NO - Norvegia 2
PT - Portogallo 2
QA - Qatar 2
SV - El Salvador 2
TT - Trinidad e Tobago 2
BN - Brunei Darussalam 1
CG - Congo 1
CM - Camerun 1
GD - Grenada 1
GP - Guadalupe 1
GT - Guatemala 1
Totale 11.694
Salva come PNG Salva come JPEG
Città #
Moscow 751
Dublin 613
Ashburn 596
Hong Kong 515
Singapore 509
Nyköping 349
Princeton 268
Dallas 248
Messina 156
San Jose 148
Beijing 137
Medford 107
Los Angeles 91
Chandler 86
Ho Chi Minh City 77
São Paulo 76
Nuremberg 61
Lauterbourg 60
Council Bluffs 55
Hanoi 50
New York 47
Jakarta 45
The Dalles 45
Redondo Beach 43
Vienna 38
Buffalo 37
Santa Clara 35
Orem 32
Guangzhou 31
Rio de Janeiro 31
Frankfurt am Main 29
Pune 29
Milan 27
Munich 26
Tianjin 26
Lappeenranta 25
Tashkent 24
Helsinki 21
Mexico City 21
Shenzhen 20
Tokyo 20
Turku 20
Amsterdam 19
Rome 19
Chennai 18
Baghdad 17
Brooklyn 17
Porto Alegre 17
Arezzo 16
Brasília 16
Shanghai 16
Johannesburg 15
Quito 15
Haiphong 14
Belo Horizonte 13
Campinas 13
London 13
Zhengzhou 13
Denver 12
Nairobi 12
Atlanta 11
Biên Hòa 11
Catania 11
Dhaka 11
Düsseldorf 11
Montreal 11
Paternò 11
Stockholm 11
Warsaw 11
Bari 10
Boston 10
Chicago 10
Guayaquil 10
Rheinfelden 10
Salvador 10
Sorocaba 10
Cairo 9
Montevideo 9
Poplar 9
Portsmouth 9
San Francisco 9
Bogotá 8
Brno 8
Buenos Aires 8
Cuiabá 8
Curitiba 8
Maceió 8
Phoenix 8
Pittsburgh 8
Prineville 8
Seattle 8
Tunis 8
Bangkok 7
Bexley 7
Boardman 7
Caracas 7
Erbil 7
Fortaleza 7
Hải Dương 7
Istanbul 7
Totale 6.258
Salva come PNG Salva come JPEG
Nome #
Overexpression of nuclear NHERF1 in advanced colorectal cancer: association with hypoxic microenvironment and tumor invasive phenotype. 170
Autophagic-Related Proteins in Brain Gliomas: Role, Mechanisms, and Targeting Agents 151
Crosstalk between ILC3s and Microbiota: Implications for Colon Cancer Development and Treatment with Immune Check Point Inhibitors 147
Cardiotoxicity Induced by Immune Checkpoint Inhibitors: What a Cardio-Oncology Team Should Know and Do 143
Circulating biomarkers as predictors of response to immune checkpoint inhibitors in NSCLC: Are we on the right path? 142
Potential predictive role of gut microbiota to immunotherapy in HCC patients: a brief review 139
Immune checkpoint inhibitors and neurotoxicity: a focus on diagnosis and management for a multidisciplinary approach 139
"Pure" hepatoid tumors of the pancreas harboring CTNNB1 somatic mutations: a new entity among solid pseudopapillary neoplasms 136
A Systematic Review on PD-1 Blockade and PD-1 Gene-Editing of CAR-T Cells for Glioma Therapy: From Deciphering to Personalized Medicine 134
A moonshot approach toward the management of cancer patients in the COVID-19 time: What have we learned and what could the Italian network of cancer centers (Alliance against Cancer, ACC) do after the pandemic wave? 129
Corticosteroids in oncology: Use, overuse, indications, contraindications. An Italian Association of Medical Oncology (AIOM)/ Italian Association of Medical Diabetologists (AMD)/ Italian Society of Endocrinology (SIE)/ Italian Society of Pharmacology (SIF) multidisciplinary consensus position paper 126
Actors on the Scene: Immune Cells in the Myeloma Niche 126
Management of Endocrine and Metabolic Toxicities of Immune-Checkpoint Inhibitors: From Clinical Studies to a Real-Life Scenario 119
A Novel Prognostic Tool in Western and Eastern Biliary Tract Cancer Patients Treated in First-line Setting: the ECSIPOT Index 118
Basics and frontiers on pancreatic cancer for radiation oncology: Target delineation, SBRT, SIB technique, MRgRT, particle therapy, immunotherapy and clinical guidelines 114
Comparison Study of the Safety Profile of Olaparib Versus Niraparib: Analysis of Real-World Data from EudraVigilance 111
Safety profile of tyrosine kinase inhibitors used in non-small-cell lung cancer: An analysis from the Italian pharmacovigilance database 108
Rare histotypes of epithelial biliary tract tumors: A literature review 106
Dihydropyrimidine Dehydrogenase Polymorphism c.2194G>A Screening Is a Useful Tool for Decreasing Gastrointestinal and Hematological Adverse Drug Reaction Risk in Fluoropyrimidine-Treated Patients 104
Neuropsychiatric adverse drug reactions with oral tyrosine kinase inhibitors in metastatic colorectal cancer: an analysis from the FDA Adverse Event Reporting System 103
Targeted therapies for KRAS-mutant non-small cell lung cancer: from preclinical studies to clinical development-a narrative review 102
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial 101
Cancer survivorship at heart: a multidisciplinary cardio-oncology roadmap for healthcare professionals 98
Challenges and pitfalls in the management of endocrine toxicities from immune checkpoint inhibitors: a case presentation of synchronous thyrotoxicosis and primary adrenal insufficiency in a melanoma patient 96
From bench to bedside: highlights from the International Dialogue on Ovarian Cancer 95
Neuropsychiatric Adverse Drug Reactions with Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumors: An Analysis from the European Spontaneous Adverse Event Reporting System 94
A Systematic Review and Meta-Analysis on the Significance of TIGIT in Solid Cancers: Dual TIGIT/PD-1 Blockade to Overcome Immune-Resistance in Solid Cancers 90
The Italian Rare Biliary tract Cancer initiative (IRaBiCa): A multicentric observational study of Gruppo Oncologico dell’Italia Meridionale (GOIM) in collaboration with Gruppo Italiano Colangiocarcinoma (GICO) 89
A randomized phase III study of fractionated docetaxel, oxaliplatin, capecitabine (low-tox) vs epirubicin, oxaliplatin and capecitabine (eox) in patients with locally advanced unresectable or metastatic gastric cancer: the lega trial 87
Moving the target on the optimal adjuvant strategy for resected pancreatic cancers: A systematic review with meta-analysis 87
Antiangiogenic agents after first line and sorafenib plus chemoembolization: A systematic review 87
Immune Checkpoint Inhibitors and the Kidney: A Focus on Diagnosis and Management for Personalised Medicine 85
FOLFIRINOX after first-line gemcitabine-based chemotherapy in advanced pancreatic cancer: a retrospective comparison with FOLFOX and FOLFIRI schedules 85
A prognostic model in patients with advanced biliary tract cancer receiving first-line chemotherapy 84
A Systematic Review on the Therapeutic Potentiality of PD-L1-Inhibiting MicroRNAs for Triple-Negative Breast Cancer: Toward Single-Cell Sequencing-Guided Biomimetic Delivery 84
Somatic BRCA Mutation in a Cholangiocarcinoma Patient for HBOC Syndrome Detection 83
Active treatment given in the last weeks of life: poor quality cancer care or justifiable behavior? 83
Association of NOS3 and ANGPT2 Gene Polymorphisms with Survival in Patients with Hepatocellular Carcinoma Receiving Sorafenib: Results of the Multicenter Prospective INNOVATE Study 83
Photodynamic therapy with zinc phthalocyanine enhances the anti-cancer effect of tamoxifen in breast cancer cell line: Promising combination treatment against triple-negative breast cancer? 82
The global burden of cancer attributable to risk factors, 2010–19: a systematic analysis for the Global Burden of Disease Study 2019 82
[Apoptosis or programmed cell death: regulatory and pathophysiological mechanisms]. FT Apoptosi, o morte cellulare programmata: meccanismi regolatori e fisiopatologia 82
Laparoscopic vs. open mesorectal excision for rectal cancer: Are these approaches still comparable? A systematic review and meta-analysis 81
Khorana score and thromboembolic risk in stage II–III colorectal cancer patients: a post hoc analysis from the adjuvant TOSCA trial 81
The molecular profiling of solid tumors by liquid biopsy: a position paper of the AIOM-SIAPEC-IAP-SIBioC-SIC-SIF Italian Scientific Societies 80
Expression and characterization of a novel recombinant cytotoxin II from Naja naja oxiana venom: A potential treatment for breast cancer 80
Biomarker phenotyping drives clinical management in axillary sentinel node: A retrospective study on women with primary breast cancer in 2002 80
[Paraneoplastic syndromes of the central nervous system] 79
STAT3 Silencing and TLR7/8 Pathway Activation Repolarize and Suppress Myeloid-Derived Suppressor Cells From Breast Cancer Patients 79
A Systematic Review of the Tumor-Infiltrating CD8+ T-Cells/PD-L1 Axis in High-Grade Glial Tumors: Toward Personalized Immuno-Oncology 78
A scoping review on the potentiality of PD-L1-inhibiting microRNAs in treating colorectal cancer: Toward single-cell sequencing-guided biocompatible-based delivery 78
A Promising Role of TGF-β Pathway in Response to Regorafenib in Metastatic Colorectal Cancer: A Case Report 78
The prognostic nutritional index predicts survival and response to first-line chemotherapy in advanced biliary cancer 77
A scoping review on the significance of programmed death-ligand 1-inhibiting microRNAs in non-small cell lung treatment: A single-cell RNA sequencing-based study 76
Anti-angiogenesis and Immunotherapy: Novel Paradigms to Envision Tailored Approaches in Renal Cell-Carcinoma 76
[Indices of disease activity in systemic lupus erythematosus. Review of the literature] 76
Metabolic disorders and gastroenteropancreatic-neuroendocrine tumors (GEP-NETs): How do they influence each other? An Italian Association of Medical Oncology (AIOM)/ Italian Association of Medical Diabetologists (AMD)/ Italian Society of Endocrinology (SIE)/ Italian Society of Pharmacology (SIF) multidisciplinary consensus position paper 75
The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib 75
Renal Disorders with Oral Tyrosine Kinase Inhibitors in Metastatic Colorectal Cancer: An Analysis from the FDA Adverse Event Reporting System Database 74
A Systematic Review to Clarify the Prognostic Values of CD44 and CD44+CD24- Phenotype in Triple-Negative Breast Cancer Patients: Lessons Learned and The Road Ahead 74
Antineoplastic dosing in overweight and obese cancer patients: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/Società Italiana Endocrinologia (SIE)/Società Italiana Farmacologia (SIF) multidisciplinary consensus position paper 74
Combination of Ipilimumab and Nivolumab in Cancers: From Clinical Practice to Ongoing Clinical Trials 74
A phase I study of capecitabine in combination with vinorelbine in advanced breast cancer 74
Bortezomib Treatment Modulates Autophagy in Multiple Myeloma 73
Fluropyrimidine single agent or doublet chemotherapy as second line treatment in advanced biliary tract cancer 73
PD-L1 silencing inhibits triple-negative breast cancer development and upregulates T-cell-induced pro-inflammatory cytokines 72
Microfluidic-Assisted Preparation of Targeted pH-Responsive Polymeric Micelles Improves Gemcitabine Effectiveness in PDAC: In Vitro Insights 72
Cardiovascular Safety Profile of BRAF and MEK Inhibitors in Melanoma: FAERS Data Through a Retrospective Disproportionality Analysis (2014–2023) 72
null 72
Hydroxy-propil-β-cyclodextrin inclusion complexes of two biphenylnicotinamide derivatives: Formulation and anti-proliferative activity evaluation in pancreatic cancer cell models 72
Extrahepatic Distal Cholangiocarcinoma vs. Pancreatic Ductal Adenocarcinoma: Histology and Molecular Profiling for Differential Diagnosis and Treatment 71
Immune Checkpoint Inhibitor-Related Myositis: From Biology to Bedside 71
Neutrophils, Crucial, or Harmful Immune Cells Involved in Coronavirus Infection: A Bioinformatics Study 71
Exploiting systems biology to investigate the gene modules and drugs in ovarian cancer: A hypothesis based on the weighted gene co-expression network analysis 70
Second-line treatments for Advanced Hepatocellular Carcinoma: A Systematic Review and Bayesian Network Meta-analysis 70
Prediction and validation of GUCA2B as the hub-gene in colorectal cancer based on co-expression network analysis: In-silico and in-vivo study 70
Genomic characterization of undifferentiated sarcomatoid carcinoma of the pancreas 68
Vaccination for herpes zoster in patients with solid tumors: a position paper on the behalf of the Associazione Italiana di Oncologia Medica (AIOM) 67
Clinical practice guidelines for diagnosis, treatment and follow-up of exocrine pancreatic ductal adenocarcinoma: Evidence evaluation and recommendations by the italian association of medical oncology (AIOM) 67
Prognostic Role and Clinical Significance of Tumor-Infiltrating Lymphocyte (TIL) and Programmed Death Ligand 1 (PD-L1) Expression in Triple-Negative Breast Cancer (TNBC): A Systematic Review and Meta-Analysis Study 66
MiR-144: A new possible therapeutic target and diagnostic/prognostic tool in cancers 66
[Common variable immunodeficiency]. FT Immunodeficienza comune variabile 66
Neuropsychiatric Adverse Events with Monoclonal Antibodies Approved for Multiple Myeloma: An Analysis from the FDA Adverse Event Reporting System 65
Unveiling cardiovascular and respiratory toxicities with monoclonal antibodies in multiple myeloma: disproportionality analysis from the FDA Adverse Event Reporting System 65
The latest findings of PD-1/PD-L1 inhibitor application in gynecologic cancers 64
Incidence of patients with bone metastases at diagnosis of solid tumors in adults: a large population-based study 63
Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world 63
mRNA-COVID19 Vaccination Can Be Considered Safe and Tolerable for Frail Patients 62
Current approaches for combination therapy of cancer: The role of immunogenic cell death 62
Identification of early diagnostic biomarkers via WGCNA in gastric cancer 61
Diabetes management in cancer patients. An Italian Association of Medical Oncology, Italian Association of Medical Diabetologists, Italian Society of Diabetology, Italian Society of Endocrinology and Italian Society of Pharmacology multidisciplinary consensus position paper 61
The combination effect of Prominin1 (CD133) suppression and Oxaliplatin treatment in colorectal cancer therapy 60
Liquid biopsy and tumor heterogeneity in metastatic solid tumors: the potentiality of blood samples 59
The importance of immune checkpoints in immune monitoring: A future paradigm shift in the treatment of cancer 58
Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study 58
Predictors of thyroid adverse events during cancer immunotherapy: a real-life experience at a single center 57
Varied functions of immune checkpoints during cancer metastasis 57
Italian oncologists and vaccinations against infectious diseases: Results of a survey of the Italian Association of Medical Oncology 56
On the Management of Drug Interactions in the Course of Concomitant Treatments for COVID-19 and Antineoplastic Agents 55
Polybrominated Diphenyl Ethers (PBDEs) and Human Health: Effects on Metabolism, Diabetes and Cancer 54
NLRP3 Inflammasome From Bench to Bedside: New Perspectives for Triple Negative Breast Cancer 54
Totale 8.506
Salva come PNG Salva come JPEG
Categoria #
all - tutte 46.226
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 46.226
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022388 0 0 0 0 0 0 0 0 8 0 0 380
2022/20231.548 307 183 131 7 28 93 32 45 663 9 13 37
2023/2024379 53 58 33 27 33 55 44 10 9 8 6 43
2024/20252.786 66 43 46 127 209 84 126 389 564 233 301 598
2025/20266.787 358 470 572 503 568 1.336 811 838 749 571 11 0
Totale 11.888